BioWorld

Nov. 6, 2007

View Archived Issues

Deaths End Novacea's Prostate Cancer Trial

Novacea Inc. and its partner Schering-Plough Corp. halted a Phase III trial of an investigational prostate cancer treatment because of a higher rate of deaths in patients receiving the drug, the firms said Monday. (BioWorld Today) Read More

Lead Therapeutics' Series A: $17M For Research In China

Read More

Immune Proteins 'Moonlight' In Brain Development, Repair

Read More

Favrille Adding $21M Via Direct Offering For FavId

Read More

Liver Disease Roundup

Read More

Other News To Note

Read More

American Heart Assoc. Roundup

Read More

Clinic Roundup

Read More